SRZNW Surrozen, Inc. Stock Quote

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	-	Perf Week	-5.31%
Market Cap	-	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	30.73M	Perf Month	-36.69%
Income	-	PEG	-	EPS next Q	-	Inst Own	-	Short Float	-	Perf Quarter	-29.14%
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	-	Perf Half Y	-20.74%
Book/sh	-	P/B	-	EPS next Y	-	ROA	-	Target Price	-	Perf Year	-
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	0.60 - 3.03	Perf YTD	-42.16%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-64.69%	Beta	-
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	78.33%	ATR	0.28
Employees	-	Current Ratio	-	Sales Q/Q	-	Oper. Margin	-	RSI (14)	42.66	Volatility	7.65% 20.38%
Optionable	No	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.22	Prev Close	1.07
Shortable	No	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	18.63K	Price	1.07
Recom	-	SMA20	-29.20%	SMA50	-17.66%	SMA200	-23.55%	Volume	0	Change	0.00%

Oct-05-21 04:30PM	Surrozen Presented Data Supporting Potential of SZN-1326 at the 2021 United European Gastroenterology Week GlobeNewswire +7.38%
Sep-23-21 08:30AM	Surrozen Announces Appointment of Liz Nguyen as Vice President and Head of Human Resources GlobeNewswire +16.27%
Aug-11-21 05:30PM	Surrozen Debuts as Publicly Traded Leader in Wnt Biology and Tissue Regeneration GlobeNewswire

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies to engage the body's existing biological repair mechanisms with potential application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 that stimulates hepatocyte regeneration, improves liver function, and reduces fibrosis; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are highly expressed in intestinal crypts. The company was founded in 2016 and is headquartered in South San Francisco, California.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience